Experimental and early investigational drugs for angina pectoris

References

• Camm AJ, Manolis A, Ambrosio G, et al. Unresolved issues in the management of chronic stable angina. Int J Cardiol. 2015;201:200–207.
   PubMed Web of Science ®Google Scholar
• Ambrosio G, Komajda M, Mugelli A, et al. Management of stable angina: A commentary on the European society of cardiology guidelines. Eur J Prev Cardiol. 2016;23:1401–1412.
   PubMed Web of Science ®Google Scholar
• Winchester DE, Pepine CJ. Angina treatments and prevention of cardiac events: an appraisal of the evidence. Eur Heart J Suppl. 2015;17:G10–G18.
   PubMed Web of Science ®Google Scholar
• Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol Rev. 2008;88:1009–1086.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: A report from the American heart association. Circulation. 2016;133:e38–e60.
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. Circulation. 2012;2012(126):e354–e471.
   Web of Science ®Google Scholar
• Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. 2013;2013(34):2949–3003.
   Google Scholar
• Elgendy IY, Bavry AA, Gong Y, et al. Long-term mortality in hypertensive patients with coronary artery disease: Results from the US cohort of the International Verapamil (SR)/Trandolapril Study. Hypertension. 2016;68(5):1110–1114.
   PubMed Web of Science ®Google Scholar
• Abrams J. Clinical practice. Chronic stable angina. N Engl J Med. 2005;352:2524–2533.
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677–687.
   PubMed Web of Science ®Google Scholar
• Elgendy IY, Conti CR, Bavry AA. Fractional flow reserve: an updated review. Clin Cardiol. 2014;37:371–380.
   PubMed Web of Science ®Google Scholar
• Rosner GF, Kirtane AJ, Genereux P, et al. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circulation. 2012;125:2613–2620.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Winchester D, Pepine CJ. Antagonist molecules in the treatment of angina. Expert Opin Pharmacother. 2013;14:2323–2342.
   PubMed Web of Science ®Google Scholar
• Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29:1327–1334.
   PubMed Web of Science ®Google Scholar
• Winchester DE, Pepine CJ. Usefulness of beta blockade in contemporary management of patients with stable coronary heart disease. Am J Cardiol. 2014;114:1607–1612.
   PubMed Web of Science ®Google Scholar
• Elgendy IY, Mahmoud A, Conti CR. Beta-blockers in the management of coronary artery disease: are we on the verge of a new paradigm shift? Recent Pat Cardiovasc Drug Discov. 2014;9:11–21.
   PubMedGoogle Scholar
• Bangalore S, Steg G, Deedwania P, et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. Jama. 2012;308:1340–1349.
   PubMed Web of Science ®Google Scholar
• Kobusiak-Prokopowicz M, Jołda-Mydłowska B, Zubkiewicz A, et al. Impact of nebivolol on levels of serum nitric oxide, plasma von Willebrand factor and exercise stress testing parameters in hypertensive and ischemic heart disease patients. Cardiol J. 2008;15:162–168.
   PubMedGoogle Scholar
• Togni M, Vigorito F, Windecker S, et al. Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovasc Drugs Ther. 2007;21:99–108.
   PubMed Web of Science ®Google Scholar
• Tagliamonte E, Cirillo T, Rigo F, et al. Ivabradine and bisoprolol on doppler-derived coronary flow velocity reserve in patients with stable coronary artery disease: beyond the heart rate. Adv Ther. 2015;32:757–767.
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm AJ. I f inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008;31:95–107.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540–548.
   PubMed Web of Science ®Google Scholar
• Ye L, Ke D, Chen Q, et al. Effectiveness of ivabradine in treating stable angina pectoris. Medicine (Baltimore). 2016;95:e3245.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–1099.
   PubMed Web of Science ®Google Scholar
• Corlentor and Procoralan [Internet]. European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan ivabradine. London: European Medicines Agency; cited 2016 Sep 22. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Corlentor_and_Procoralan/human_referral_prac_000044.jsp&mid=WC0b01ac05805c516f
   Google Scholar
• Saad M, Mahmoud A, Elgendy IY, et al. Ranolazine in cardiac arrhythmia. Clin Cardiol. 2016;39:170–178.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. Jama. 2004;291:309–316.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–1382.
   PubMed Web of Science ®Google Scholar
• Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566–575.
   PubMed Web of Science ®Google Scholar
• Weisz G, Généreux P, Iñiguez A, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:136–145.
   PubMed Web of Science ®Google Scholar
• Kawanishi DT, Reid CL, Morrison EC, et al. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol. 1992;19:409–417.
   PubMed Web of Science ®Google Scholar
• Wei J, Wu T, Yang Q, et al. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol. 2011;146:4–12.
   PubMed Web of Science ®Google Scholar
• IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269–1275.
   PubMed Web of Science ®Google Scholar
• Horinaka S, Yabe A, Yagi H, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J. 2010;74:503–509.
   PubMed Web of Science ®Google Scholar
• Sani HD, Eshraghi A, Nezafati MH, et al. Nicorandil versus nitroglycerin for symptomatic relief of angina in patients with slow coronary flow phenomenon: A randomized clinical trial. J Cardiovasc Pharmacol Ther. 2015;20:401–416.
   PubMed Web of Science ®Google Scholar
• Van Hove C, Carreer-Bruhwyler F, Géczy J, et al. Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina. Atherosclerosis. 2005;180:399–405.
   PubMed Web of Science ®Google Scholar
• Messin R, Opolski G, Fenyvesi T, et al. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris. Int J Cardiol. 2005;98:79–89.
   PubMed Web of Science ®Google Scholar
• Barbato E, Herman A, Benit E, et al. Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial. Atherosclerosis. 2015;240:351–354.
   PubMed Web of Science ®Google Scholar
• Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005;4:CD003614.
   PubMed Web of Science ®Google Scholar
• Olivotto I, Hellawell JL, Farzaneh-Far R, et al. Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial. Circ Heart Fail. 2016;9:e002764.
   PubMed Web of Science ®Google Scholar
• Meyer BJ, Amann FW. Additional antianginal efficacy of amiodarone in patients with limiting angina pectoris. Am Heart J. 1993;125:996–1001.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, Van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–678.
   PubMed Web of Science ®Google Scholar
• Feng Y, LoGrasso PV, Defert O, et al. Rho kinase (ROCK) inhibitors and their therapeutic potential. J Med Chem. 2016;59:2269–2300.
   PubMed Web of Science ®Google Scholar
• Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46:1803–1811.
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Mohri M, Inokuchi K, et al. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol. 2007;49:117–121.
   PubMed Web of Science ®Google Scholar
• Oh KS, Oh BK, Park CH, et al. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865). Eur J Pharmacol. 2013;702:218–226.
   PubMed Web of Science ®Google Scholar
• Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001;104:1114–1118.
   PubMed Web of Science ®Google Scholar
• Kyriakides ZS, Kremastinos DT, Kolettis TM, et al. Acute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Circulation. 2000;102:1937–1943.
   PubMed Web of Science ®Google Scholar
• Sesti C, Simkhovich BZ, Kalvinsh I, et al. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J Cardiovasc Pharmacol. 2006;47:493–499.
   PubMed Web of Science ®Google Scholar
• Dzerve V, Matisone D, Pozdnyakov Y, et al. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. Sem Cardiovasc Med. 2010;16:1–8.
   Google Scholar
• Dzerve V, MILSS I Study Group. A dose-dependent improvement in exercise tolerance in patients with stable angina treated with mildronate: a clinical trial “MILSS I”. Medicina (Kaunas). 2011;47:544–551.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Schang SJ, Bemiller CR. Effects of perhexiline on coronary hemodynamic and myocardial metabolic responses to tachycardia. Circulation. 1974;49:887–893.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Schang SJ, Bemiller CR. Effects of perhexiline on symptomatic and hemodynamic responses to exercise in patients with angina pectoris. Am J Cardiol. 1974;33:806–812.
   PubMed Web of Science ®Google Scholar
• Roberts RK, Cohn D, Petroff V, et al. Liver disease induced by perhexiline maleate. Med J Aust. 1981;2:553–554.
   PubMed Web of Science ®Google Scholar
• Bouche P, Bousser MG, Peytour MA, et al. Perhexiline maleate and peripheral neuropathy. Neurology. 1979;29:739–743.
   PubMed Web of Science ®Google Scholar
• Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation. 1990;81:1260–1270.
   PubMed Web of Science ®Google Scholar
• Phan TT, Shivu GN, Choudhury A, et al. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope. Eur J Heart Fail. 2009;11:881–886.
   PubMed Web of Science ®Google Scholar
• Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161–2167.
   PubMed Web of Science ®Google Scholar
• Rajendra NS, Ireland S, George J, et al. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol. 2011;58:820–828.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–3318.
   PubMed Web of Science ®Google Scholar
• Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. 2007;19:176–182.
   PubMed Web of Science ®Google Scholar
• Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666–1670.
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–1911.
   PubMed Web of Science ®Google Scholar
• Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161:443–449.
   PubMed Web of Science ®Google Scholar
• Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. Jama. 2013;310:1829–1836.
   PubMed Web of Science ®Google Scholar
• Attanasio S, Schaer G. Therapeutic angiogenesis for the management of refractory angina: current concepts. Cardiovasc Ther. 2011;29:e1–e11.
   PubMed Web of Science ®Google Scholar
• Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007;50:1038–1046.
   PubMed Web of Science ®Google Scholar
• Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007;115:3165–3172.
   PubMed Web of Science ®Google Scholar
• Tse HF, Thambar S, Kwong YL, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J. 2007;28:2998–3005.
   PubMed Web of Science ®Google Scholar
• Van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. Jama. 2009;301:1997–2004.
   PubMed Web of Science ®Google Scholar
• Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428–436.
   PubMed Web of Science ®Google Scholar
• Povsic TJ, Junge C, Nada A, et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013;165:854–861.
   PubMed Web of Science ®Google Scholar
• Wang JM. Meta-analysis of comparative study on guanxinning injection in the treatment of unstable angina pectoris. Zhong Guo Yao Fang. 2011;22:1810–1812.
   Google Scholar
• Zhang X, Wang H, Chang Y, et al. An overview of meta-analyses of danhong injection for unstable angina. Evid Based Complement Alternat Med. 2015;2015:358028.
   PubMed Web of Science ®Google Scholar